PRESENTATION TITLE
Pharmacogenomics: Discovery and Translation

PRESENTATION HIGHLIGHT
Pharmacogenomics is a study of the role of individual variation in variation in drug response. The attention has long been focused on functional SNPs in coding region of a gene, genes mainly encoding CYPs. However, these known genetic variants do not fully explain the individual variation in response to the drugs metabolized by these enzymes, indicating other factors are involved. Increasingly we found that rare functional SNPs or SNPs in genes, such as transcription factors regulating CYPs all can contribute to drug response. Finally clinical phenotypes are not only influence by host SNP genotype but potentially chemical compound either endogenous or exogenous compounds, like drugs. Ultimately these genetic biomarkers should be incorporated into predictive algorithm to guild individualized therapy.

PRESENTER
Leiwei Wang, MD, PhD
Bernard and Edith Waterman Director, Pharmacogenomics Program, Center for Individualized Medicine
Chair, Pharmacology
Mayo Clinic, Rochester, MN

PRESENTER BIO

Liewei Wang, M.D., Ph.D., is a professor of pharmacology at Mayo Clinic College of Medicine and Science in Rochester, Minnesota. She is the Bernard and Edith Waterman Director, Pharmacogenomics Program, Center for Individualized Medicine. She is also a member of the American Society of Clinical Investigation (ASCI).

The research of Liewei Wang, M.D., Ph.D., is focused on pharmacogenomics, a critical component of individualized medicine that studies the role of inheritance in variation in drug response. Patients treated with the same dose or regimen of a drug can display different responses, ranging from lack of efficacy to severe toxicity. Dr. Wang's research interests include identifying additional treatment options for chemotherapy-resistant cancers. She is an investigator in the Mayo Clinic Breast Cancer SPORE.

Dr. Wang's laboratory uses various high-throughput omics tools, including genomics, transcriptomics and metabolomics, to identify biomarkers that can help predict clinical response. At the same time, her lab uses various models, including cells, patient-derived xenografts and patient samples, to validate and understand the biology underlying these biomarkers.

LEARNING OBJECTIVES 
After the presentation, attendees will be able to:

• Define pharmacogenomics
• Describe genetic variation might affect function
• Recognize family of transcription factors identified to regulate CYP genes

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.